Revenue (Tables)

6 Months Ended

Oct. 30, 2020

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The table below illustrates net sales by segment and division for the three and six months ended October 30, 2020 and October 25, 2019:

	Three months ended(1)				Six months ended(1)
(in millions)	October 30, 2020		October 25, 2019		October 30, 2020		October 25, 2019
Cardiac Rhythm & Heart Failure	$	1,426	$	1,426	$	2,673	$	2,807
Coronary & Structural Heart	831		955		1,611		1,896
Aortic, Peripheral, & Venous	468		474		873		942
Cardiac & Vascular Group	2,725		2,855		5,158		5,645
Surgical Innovations	1,393		1,454		2,473		2,871
Respiratory, Gastrointestinal, & Renal	893		688		1,613		1,371
Minimally Invasive Therapies Group	2,285		2,142		4,086		4,242
Cranial & Spinal Technologies	1,071		1,117		2,015		2,167
Specialty Therapies	581		575		1,035		1,138
Neuromodulation	411		420		725		818
Restorative Therapies Group	2,063		2,112		3,774		4,124
Diabetes Group	574		596		1,136		1,188
Total	$	7,647	$	7,706	$	14,154	$	15,199

(1) Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.

During the first quarter of fiscal year 2021, the Company realigned the divisions within the Restorative Therapies Group to the following: Cranial & Spinal Technologies (includes Core Spine and Biologics, Enabling Technologies, and China Orthopedics), Specialty Therapies (includes ENT, Pelvic Health, and Neurovascular), and Neuromodulation (includes Pain Therapies, Brain Modulation, and Interventional). As a result, net sales for fiscal year 2020 have been recast to adjust for this realignment.

The table below illustrates net sales by market geography for each segment for the three and six months ended October 30, 2020 and October 25, 2019:

	U.S.(1)(4)				Non-U.S. Developed Markets(2)(4)				Emerging Markets(3)(4)
	Three months ended				Three months ended				Three months ended
(in millions)	October 30, 2020		October 25, 2019		October 30, 2020		October 25, 2019		October 30, 2020		October 25, 2019
Cardiac & Vascular Group	$	1,377	$	1,455	$	945	$	890	$	404	$	510
Minimally Invasive Therapies Group	996		922		837		782		452		438
Restorative Therapies Group	1,397		1,440		426		416		240		256
Diabetes Group	284		311		238		226		51		59
Total	$	4,054	$	4,129	$	2,446	$	2,315	$	1,147	$	1,262
	U.S.(1)(4)				Non-U.S. Developed Markets(2)(4)				Emerging Markets(3)(4)
	Six months ended				Six months ended				Six months ended
(in millions)	October 30, 2020		October 25, 2019		October 30, 2020		October 25, 2019		October 30, 2020		October 25, 2019
Cardiac & Vascular Group	$	2,582	$	2,816	$	1,798	$	1,820	$	778	$	1,009
Minimally Invasive Therapies Group	1,718		1,835		1,556		1,573		811		834
Restorative Therapies Group	2,533		2,778		802		842		439		504
Diabetes Group	572		618		465		457		100		113
Total	$	7,405	$	8,046	$	4,621	$	4,692	$	2,128	$	2,460

(1)U.S. includes the United States and U.S. territories.

(2)Non-U.S. developed markets include Japan, Australia, New Zealand, Korea, Canada, and the countries within Western Europe.

(3)Emerging markets include the countries of the Middle East, Africa, Latin America, Eastern Europe, and the countries of Asia that are not included in the non-U.S. developed markets, as defined above.

(4)Revenue amounts have intentionally been rounded to the nearest million and, therefore, may not sum.